Abstract
Electronic portal imaging device-based in vivo dosimetry with a commercial product was performed for 10 prostate cancer patients treated with an air-filled endorectal balloon. With the conventional in vivo method the verification results were outside of our clinical acceptance criteria for all patients. The in aqua vivo method, originally developed for lung cancer treatments, proved to be a practical solution to this problem. On average the percentage of points within γ agreement of 3% and 3 mm significantly improved from 90.9% ± 2.5% (1SD) for the conventional in vivo method to 99.0% ± 1.0% (1SD) for the in aqua vivo method.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
